Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Hansson

Showing results (141-150 of 199) with videos related to

Pageof 20
Sort By:
Cancer Immunology, Immunotherapy : CII|February 14, 2009
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanomaHildur Helgadottir, Emilia Andersson, Lisa Villabona, et al.
Cell Death & Disease|October 20, 2017
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cellsAlireza Azimi, Rainer Tuominen, Fernanda Costa Svedman, et al.
Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.
Trials|August 10, 2014
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trialRoger Olofsson, Lars Ny, Malin Sternby Eilard, et al.
The Lancet. Oncology|November 9, 2002
Genetic testing for melanomaRichard Kefford, Julia Newton Bishop, Margaret Tucker, et al.
Cancers|February 25, 2022
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)Ylva Naeser, Hildur Helgadottir, Johan Hansson, et al.
Scientific Reports|August 23, 2019
Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in MelanomaSoudabeh Rad Pour, Hiromasa Morikawa, Narsis A Kiani, et al.
Trials|August 7, 2015
Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trialRoger Olofsson Bagge, Lars Ny, Charlotta All-Ericsson, et al.
Molecular Systems Biology|March 7, 2018
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitorsAlireza Azimi, Stefano Caramuta, Brinton Seashore-Ludlow, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Pageof 20

Showing results (141-150 of 199) with videos related to

Sort By:
Pageof 20
Cancer Immunology, Immunotherapy : CII|February 14, 2009
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanomaHildur Helgadottir, Emilia Andersson, Lisa Villabona, et al.
Cell Death & Disease|October 20, 2017
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cellsAlireza Azimi, Rainer Tuominen, Fernanda Costa Svedman, et al.
Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.
Trials|August 10, 2014
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trialRoger Olofsson, Lars Ny, Malin Sternby Eilard, et al.
The Lancet. Oncology|November 9, 2002
Genetic testing for melanomaRichard Kefford, Julia Newton Bishop, Margaret Tucker, et al.
Cancers|February 25, 2022
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)Ylva Naeser, Hildur Helgadottir, Johan Hansson, et al.
Scientific Reports|August 23, 2019
Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in MelanomaSoudabeh Rad Pour, Hiromasa Morikawa, Narsis A Kiani, et al.
Trials|August 7, 2015
Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trialRoger Olofsson Bagge, Lars Ny, Charlotta All-Ericsson, et al.
Molecular Systems Biology|March 7, 2018
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitorsAlireza Azimi, Stefano Caramuta, Brinton Seashore-Ludlow, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Pageof 20